GLP-1 Drugs Show Wider Benefits Beyond Weight Loss, Editorial Finds

An editorial published in the journal Obesity by Dr. Steven Heymsfield of LSU's Pennington Biomedical Research Center and Dr. Adam Gilden of the University of Colorado has surveyed emerging evidence on effects of GLP-1 receptor agonists — the class of drugs including Ozempic, Wegovy, Mounjaro and Zepbound — that go beyond their original purpose of treating obesity and diabetes. "Most of the unanticipated side effects of GLP-1 receptor agonists have been positive," the authors wrote.

As millions of people now use these medications, Heymsfield and Gilden point to evidence that GLP-1 drugs may reduce inflammation and lower the risk of certain cardiovascular and musculoskeletal conditions. Other emerging research suggests they may reduce alcohol consumption and the risk of some substance use disorders, though the authors say further clinical trials are needed to confirm whether those effects hold up.

The editorial also flags unresolved concerns about lean body mass and nutrition: some of the weight lost during GLP-1 treatment comes from lean mass, including muscle, making exercise and proper nutrition important areas of study. Because the drugs reduce appetite, some patients may also face a higher risk of micronutrient deficiencies.

Heymsfield and Gilden identify three priorities for future research: determining the mechanisms behind the drugs' apparent anti-inflammatory effects, using randomized trials to better characterize changes in lean body mass and ways to preserve muscle, and running larger randomized trials to establish whether the medications can reduce alcohol use disorders.